230 related articles for article (PubMed ID: 4016793)
1. High-performance liquid chromatographic and enzyme-inhibition assays of methotrexate concentrations in serum from patients receiving high-dose therapy: tight binding of some methotrexate to a protein that could be dihydrofolate reductase.
Iven H; Bartels H
Cancer Treat Rep; 1985; 69(7-8):825-32. PubMed ID: 4016793
[TBL] [Abstract][Full Text] [Related]
2. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.
Jolivet J; Chabner BA
J Clin Invest; 1983 Sep; 72(3):773-8. PubMed ID: 6193143
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate and 7-hydroxymethotrexate: serum level monitoring by high-performance liquid chromatography.
Canfell C; Sadée W
Cancer Treat Rep; 1980 Jan; 64(1):165-9. PubMed ID: 7379052
[TBL] [Abstract][Full Text] [Related]
4. High-presssure liquid chromatographic determination of methotrexate and its major metabolite, 7-hydroxymethotrexate, in human plasma.
Watson E; Cohen JL; Chan KK
Cancer Treat Rep; 1978 Mar; 62(3):381-7. PubMed ID: 647697
[TBL] [Abstract][Full Text] [Related]
5. A simple radiometric assay for methotrexate and other folate antagonists.
Hayman RJ; Fong H; Van der Weyden MB
J Lab Clin Med; 1979 Mar; 93(3):480-4. PubMed ID: 311801
[TBL] [Abstract][Full Text] [Related]
6. A direct ligand-binding radioassay for the measurement of methotrexate in tissues and biological fluids.
Arons E; Rothenberg SP; Costa MD; Fischer C; Iqbal MP
Cancer Res; 1975 Aug; 35(8):2033-8. PubMed ID: 807320
[TBL] [Abstract][Full Text] [Related]
7. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Chen G; Wright JE; Rosowsky A
Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
[TBL] [Abstract][Full Text] [Related]
8. [Serum monitoring of methotrexate (MTX) and 7-hydroxymethotrexate concentrations in patients treated with MTX using high-pressure liquid chromatography (HPLC) and comparison of serum MTX levels between HPLC method and fluorescence polarization immunoassay (FPIA)].
Sakamoto S; Matsuhisa T; Miyoshi K; Naruse R; Urayama H; Shimokawa T; Okabe K; Toki H; Motoi M; Moriwaki S
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1119-25. PubMed ID: 2053771
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of resistance to antifolates, a review.
Banerjee D; Ercikan-Abali E; Waltham M; Schnieders B; Hochhauser D; Li WW; Fan J; Gorlick R; Goker E; Bertino JR
Acta Biochim Pol; 1995; 42(4):457-64. PubMed ID: 8852336
[TBL] [Abstract][Full Text] [Related]
10. Interference of 7-hydroxymethotrexate with the determination of methotrexate in plasma samples from children with acute lymphoblastic leukemia employing routine clinical assays.
Fotoohi K; Skärby T; Söderhäll S; Peterson C; Albertioni F
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Mar; 817(2):139-44. PubMed ID: 15686977
[TBL] [Abstract][Full Text] [Related]
11. Increasing methotrexate resistance by combination of active-site mutations in human dihydrofolate reductase.
Volpato JP; Fossati E; Pelletier JN
J Mol Biol; 2007 Oct; 373(3):599-611. PubMed ID: 17868689
[TBL] [Abstract][Full Text] [Related]
12. Formation of 7-hydroxymethotrexate polyglutamyl derivatives and their cytotoxicity in human chronic myelogenous leukemia cells, in vitro.
Fabre G; Goldman ID
Cancer Res; 1985 Jan; 45(1):80-5. PubMed ID: 2578101
[TBL] [Abstract][Full Text] [Related]
13. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. III. Human serum albumin-methotrexate derivative, its preparation and basic testing.
Bures L; Bostík J; Motycka K; Spundová M; Rehák L
Neoplasma; 1988; 35(3):329-42. PubMed ID: 3405341
[TBL] [Abstract][Full Text] [Related]
14. Establishment of dihydrofolate reductase-increased human cell lines and relationship between dihydrofolate reductase levels and gene copy.
Domin BA; Grill SP; Cheng Y
Cancer Res; 1983 May; 43(5):2155-8. PubMed ID: 6831441
[TBL] [Abstract][Full Text] [Related]
15. Monitoring the administration of methotrexate in antimetabolite therapy.
Epstein E; Baginski ES; Zac B
Ann Clin Lab Sci; 1976; 6(4):312-7. PubMed ID: 9024
[TBL] [Abstract][Full Text] [Related]
16. [Methotrexate and its drug resistance].
Nagura E
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2882-7. PubMed ID: 3178237
[TBL] [Abstract][Full Text] [Related]
17. Transgenic mice expressing the tyr22 variant of murine DHFR: protection of transgenic marrow transplant recipients from lethal doses of methotrexate.
James RI; May C; Vagt MD; Studebaker R; McIvor RS
Exp Hematol; 1997 Nov; 25(12):1286-95. PubMed ID: 9357973
[TBL] [Abstract][Full Text] [Related]
18. In vivo methotrexate kinetics and metabolism in human hematopoietic cells. Clinical significance of methotrexate concentrations in erythrocytes.
Schrøder H
Dan Med Bull; 1990 Feb; 37(1):22-40. PubMed ID: 2178886
[TBL] [Abstract][Full Text] [Related]
19. Activity of free and carrier-bound methotrexate against transport-deficient and high dihydrofolate dehydrogenase-containing methotrexate-resistant L1210 cells.
Chu BC; Fan CC; Howell SB
J Natl Cancer Inst; 1981 Jan; 66(1):121-4. PubMed ID: 6935452
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate dose-escalation studies in transgenic mice and marrow transplant recipients expressing drug-resistant dihydrofolate reductase activity.
May C; James RI; Gunther R; McIvor RS
J Pharmacol Exp Ther; 1996 Sep; 278(3):1444-51. PubMed ID: 8819532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
